[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"YangPan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100622501","effects-of-targeted-temporal-interference-stimulation-of-cerebellar-nuclei-on-tremor-and-gait-disturbance-in-parkinsons-disease-patients-100622501",false,"NCT07384442","Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's Disease Patients","Inclusion Criteria:\n\n* 1.Aged 50 years or older;\n* 2.Confirmed diagnosis of idiopathic Parkinson's disease (IPD) according to the 2015 MDS diagnostic criteria, with tremor and gait disturbance;\n* 3.Disease duration ≥2 years after diagnosis, stable condition, and ability to cooperate with study assessment and intervention;\n* 4.Stable medication dosage for at least 4 weeks prior to the trial;\n* 5.Good response to Levodopa therapy;\n* 6.Capable of independent walking (without assistive devices) for at least 5 minutes and able to complete gait testing independently.\n* 7.Signed informed consent form, with the participant or their legal guardian able to understand and willing to participate in this study.\n\nExclusion Criteria:\n\n* 1.History or confirmed diagnosis of severe mental disorders, such as depression, anxiety disorders, schizophrenia spectrum disorders, and bipolar disorder;\n* 2.The subject has clinically defined neurological conditions (assessed through self-report), including but not limited to: any disease potentially associated with increased intracranial pressure, space-occupying lesions, stroke history, transient ischemic attack (TIA) within the past two years, cerebral aneurysm, dementia, multiple sclerosis;\n* 3.Severe cognitive impairment, Mini-Mental State Examination (MMSE) score \\\u003C22, or inability to independently complete questionnaires;\n* 4.Inability to read or understand Chinese;\n* 5.Use of other neuromodulatory therapies within the past 3 months;\n* 6.Presence of musculoskeletal or orthopedic conditions (e.g., severe arthritis, recent fractures) that significantly interfere with gait or balance;\n* 7.Presence of metal implants (e.g., Deep Brain Stimulation, cardiac pacemakers) or contraindications for MRI\u002FTIS;\n* 8.Current use of medications that affect dopamine levels (e.g., antipsychotics);\n* 9.Severe cardiovascular disease or other unstable medical conditions that preclude physical exertion or study participation;","ALL","50 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this clinical trial is to explore the effects of cerebellar nuclei TIS stimulation on improving tremor and gait disorders in PD patients. Through randomized double-blind grouping, the differences in efficacy between TIS intervention and sham stimulation intervention for tremor and gait disorders in PD patients will be compared.",[25,26],"Parkinson's Disease","Movement Disorders",[25,28,26,29,30,31],"Cerebellar Nuclei","Tremor","Gait","Temporal Interference Stimulation","NOT_YET_RECRUITING","2026-06-09",{"date":35,"type":36},"2026-06-10","ACTUAL",{"date":38,"type":19},"2026-08-19",{"date":40,"type":19},"2026-12-31",{"name":42,"class":43},"YangPan","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":20,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100622500","phase-4-effects-of-lemborexant-on-motor-sleep-comorbidity-in-parkinsons-disease-100622500","NCT07384429","Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease","Study for the Dual Orexin Receptor Antagonist Lemborexant in Improving Motor-Sleep Comorbidity in Parkinson's Disease","Inclusion Criteria:\n\n* 1\\. Aged 50 years or older;\n* 2\\. Diagnosed with idiopathic Parkinson's disease according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease (2015), with a Hoehn \\& Yahr stage of 1 to 4;\n* 3\\. Disease duration of ≥ 2 years since diagnosis, clinically stable, and able to comply with the research assessments and interventions;\n* 4\\. Diagnosis of insomnia disorder meeting the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), with an Insomnia Severity Index (ISI) score of ≥ 15;\n* 5\\. Stable medication regimen for at least 4 weeks prior to the study;\n* 6\\. Signed informed consent form, with the participant or their legal guardian able to understand and willing to participate in this study.\n\nExclusion Criteria:\n\n* 1\\. History of or diagnosis with a severe psychiatric disorder, such as depression, anxiety disorders, schizophrenia spectrum disorders, or bipolar disorder;\n* 2\\. Presence of a clinically defined neurological disorder (assessed via self-report), including but not limited to: any condition potentially associated with increased intracranial pressure, space-occupying brain lesions, history of stroke, transient ischemic attack within the past 2 years, cerebral aneurysm, dementia, or multiple sclerosis;\n* 3\\. Severe cognitive impairment (Mini-Mental State Examination (MMSE) score below 24) or inability to complete questionnaires independently;\n* 4\\. Chronic obstructive pulmonary disease (COPD) or any lifelong history of sleep-related breathing disorders, such as sleep apnea;\n* 5\\. Excessive daytime sleepiness, defined as self-reported daily daytime napping ≥ 1 hour per day on ≥ 3 days per week;\n* 6\\. Regular caffeine consumption;\n* 7\\. Use of any orexin receptor related medication within the past 3 months.\n* 8\\. Previous history of cataplexy or known reduced orexin levels;\n* 9\\. Inability to read or understand Chinese;\n* 10\\. Use of other sleep-promoting medications within the past 3 months.",{"count":53,"type":19},44,[55],"PHASE4","The aim of this study is to explore the effects of the dual orexin receptor antagonist Lemborexant on improving motor and sleep comorbidity in patients with Parkinson's disease. This study will provide clinical evidence for the application of dual orexin receptor antagonists in the treatment of Parkinson's Disease.",[25,58,59],"Insomnia","Motor Disorder",[25,61,62,58,59],"Lemborexant","orexin receptor antagonist",{"date":64,"type":36},"2026-06-11",{"date":38,"type":19},{"date":67,"type":19},"2026-12-01",{"name":42,"class":43},""]